دورية أكاديمية
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
| العنوان: | Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. |
|---|---|
| المؤلفون: | Cornely, O.A., Vehreschild, MJGT, Adomakoh, N., Georgopali, A., Karas, A., Kazeem, G., Guery, B. |
| المصدر: | European journal of clinical microbiology & infectious diseases, vol. 38, no. 6, pp. 1187-1194 |
| سنة النشر: | 2019 |
| المجموعة: | Université de Lausanne (UNIL): Serval - Serveur académique lausannois |
| مصطلحات موضوعية: | Aged, 80 and over, Anti-Bacterial Agents/administration & dosage, Anti-Bacterial Agents/pharmacology, Clostridium Infections/drug therapy, Clostridium Infections/pathology, Clostridium difficile/classification, Clostridium difficile/drug effects, Clostridium difficile/genetics, Feces/microbiology, Female, Fidaxomicin/administration & dosage, Fidaxomicin/pharmacology, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Ribotyping, Treatment Outcome, Vancomycin/administration & dosage, Vancomycin/pharmacology, Antibacterial agents, Clostridium difficile infection, Cohort analyses, Randomised controlled trial |
| الوصف: | Poor outcomes following Clostridium difficile infection (CDI) have been associated with advanced age, presence of cancer and C. difficile PCR-ribotype 027. The impact of baseline risk factors on clinical outcomes was evaluated using data from the EXTEND study, in which rate of sustained clinical cure (SCC) in the overall population was significantly higher with an extended-pulsed fidaxomicin (EPFX) regimen than with vancomycin. Patients aged ≥ 60 years received EPFX (fidaxomicin 200 mg twice daily, days 1-5; once daily on alternate days, days 7-25) or vancomycin (125 mg four times daily, days 1-10). We analysed outcomes by advanced age, cancer diagnosis, CDI severity, prior CDI occurrence and infection with PCR-ribotype 027. The primary endpoint was SCC 30 days after end of treatment (EOT; clinical response at test-of-cure with no subsequent recurrence). SCC rates 30 days after EOT did not differ significantly between EPFX (124/177, 70.1%) and vancomycin (106/179, 59.2%) regardless of age, cancer diagnosis, CDI severity and prior CDI. In patients with PCR-ribotype 027, SCC rate 30 days after EOT was significantly higher with EPFX (20/25, 80%) than with vancomycin (9/22, 40.9%) (treatment difference, 39.1%; 95% CI, 13.2-64.9; P = 0.006). Subgroup analyses from the EXTEND study suggest that EPFX is efficacious as a potential treatment for CDI regardless of age, cancer diagnosis, infection with PCR-ribotype 027, CDI severity or prior CDI. ClinicalTrials.gov identifier: NCT02254967. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0934-9723 |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/30911926; info:eu-repo/semantics/altIdentifier/eissn/1435-4373; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EDFE031C4B470; https://serval.unil.ch/notice/serval:BIB_EDFE031C4B47Test; urn:issn:0934-9723; https://serval.unil.ch/resource/serval:BIB_EDFE031C4B47.P001/REF.pdfTest; http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_EDFE031C4B470Test |
| DOI: | 10.1007/s10096-019-03525-y |
| الإتاحة: | https://doi.org/10.1007/s10096-019-03525-yTest https://serval.unil.ch/notice/serval:BIB_EDFE031C4B47Test https://serval.unil.ch/resource/serval:BIB_EDFE031C4B47.P001/REF.pdfTest http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_EDFE031C4B470Test |
| حقوق: | info:eu-repo/semantics/openAccess ; CC BY 4.0 ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.8B823193 |
| قاعدة البيانات: | BASE |
| تدمد: | 09349723 |
|---|---|
| DOI: | 10.1007/s10096-019-03525-y |